Roquefort Therapeutics (LON:ROQ) Shares Down 9.7% – Should You Sell?

Roquefort Therapeutics plc (LON:ROQ)’s share price traded down 9.7% during mid-day trading on Tuesday . The stock traded as low as GBX 1.39 ($0.02) and last traded at GBX 1.40 ($0.02). 510,395 shares changed hands during trading, a decline of 77% from the average session volume of 2,232,834 shares. The stock had previously closed at GBX 1.55 ($0.02).

Roquefort Therapeutics Trading Down 4.0%

The firm has a market capitalization of £1.89 million, a P/E ratio of -1.23 and a beta of 0.05. The company has a quick ratio of 3.07, a current ratio of 0.79 and a debt-to-equity ratio of 12.37. The firm’s 50-day simple moving average is GBX 1.67 and its 200-day simple moving average is GBX 2.43.

Roquefort Therapeutics (LON:ROQ) last announced its earnings results on Wednesday, April 30th. The company reported GBX (0.75) (($0.01)) earnings per share (EPS) for the quarter. Roquefort Therapeutics had a negative net margin of 57,057.07% and a negative return on equity of 29.57%.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.